There seems to be a lot of posts about Misoprostol but no talk of the increased risk this drug puts women at for uterine rupture. It can be quite a nasty drug and the pharmaceutical company that manufacture misoprostol aka cytotec have issued warnings against using the drug for women during childbirth.
Love Abby > LJG <[EMAIL PROTECTED]> wrote: > > > > Ovid Technologies, Inc. Email Service > ------------------------------ > Results: Obstetrics & Gynecology > > (C) 2005 The American College of Obstetricians and Gynecologists > > Volume 105(4) Supplement, April 2005, p 39S > > Prophylactic Use of Misoprostol in the Third Stage of Labor [Papers on > Current Clinical and Basic Investigation: Poster Sessions: Monday, May > 9, > 2005: Obstetrics] > > Baskett, Thomas F. MB; Persad, Vidia MB; Clough, Heidi RN; Young, David > MD > Dalhousie University, Halifax, Nova Scotia, Canada (Baskett) > > ---------------------------------------------- > > Outline > > OBJECTIVE: > > METHODS: > > RESULTS: > > CONCLUSIONS: > > OBJECTIVE: > > To assess the effectiveness of oral misoprostol in comparison with > intravenous oxytocin in reducing bleeding during the third stage of > labor. > > METHODS: > > A double-blind, randomized controlled trial comparing oral misoprostol > 400 > [mu]g and intravenous oxytocin 5 U, given after delivery of the anterior > shoulder of the fetus, was performed. The primary outcome was a > hematocrit > drop greater than 10% at 24 hours postpartum. Secondary outcomes > included > hemoglobin drop greater than 30%, need for additional oxytocics, blood > loss > greater than 1,000 mL, manual removal of placenta, blood transfusion, > and > the adverse effects of shivering and fever. > > RESULTS: > > Results for the intravenous oxytocin (n = 311) and oral misoprostol (n = > 311) groups are as follows (expressed as percentages of each group): > hematocrit drop greater than 10%, 3.4% and 3.7%, respectively (P = NS); > hemoglobin greater than 30%, 8.9% and 10.2%, respectively (P = NS); > blood > loss greater than 1,000 mL, 2.3% and 4.5%, respectively (P = NS); manual > removal of placenta, 8.0% and 8.0%, respectively (P = NS); additional > oxytocics, 40.5% and 51.1%, respectively (P P P > > CONCLUSIONS: > > Oral misoprostol is as effective as intravenous oxytocin in reducing > loss at > delivery but is associated with an increased need for additional > oxytocic > drugs. The adverse effects of shivering and fever were only present with > misoprostol but were not clinically troublesome.Accession Number: > 00006250-200504001-00088 > > > -- > This mailing list is sponsored by ACE Graphics. > Visit <http://www.acegraphics.com.au> to subscribe or unsubscribe. -- This mailing list is sponsored by ACE Graphics. Visit <http://www.acegraphics.com.au> to subscribe or unsubscribe.
